ABC Arbitrage SA Acquires Shares of 1,970 Regeneron Pharmaceuticals, Inc. $REGN

ABC Arbitrage SA bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,970 shares of the biopharmaceutical company’s stock, valued at approximately $1,108,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cove Private Wealth LLC raised its stake in Regeneron Pharmaceuticals by 8.7% during the 3rd quarter. Cove Private Wealth LLC now owns 500 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 40 shares during the period. Wealthfront Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 28.7% during the third quarter. Wealthfront Advisers LLC now owns 5,940 shares of the biopharmaceutical company’s stock valued at $3,340,000 after acquiring an additional 1,325 shares in the last quarter. AlTi Global Inc. raised its position in shares of Regeneron Pharmaceuticals by 11.8% during the third quarter. AlTi Global Inc. now owns 464 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 49 shares during the period. Oppenheimer & Co. Inc. raised its position in shares of Regeneron Pharmaceuticals by 7.2% during the third quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock worth $13,334,000 after purchasing an additional 1,597 shares during the period. Finally, Linden Thomas Advisory Services LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 4.2% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 4,413 shares of the biopharmaceutical company’s stock worth $2,481,000 after purchasing an additional 178 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,636 shares of company stock valued at $2,862,920 over the last three months. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 3.2%

NASDAQ:REGN opened at $778.97 on Thursday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The firm has a market capitalization of $81.87 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 2.03 and a beta of 0.40. The business has a fifty day moving average price of $759.25 and a 200-day moving average price of $662.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the business earned $12.07 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent analyst reports. Scotiabank upped their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Oppenheimer restated an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Evercore boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.